Exact Sciences (EXAS) Tops Q4 EPS by 27c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Exact Sciences (EXAS) PT Lowered to $65 at BTIG
February 20, 2025 6:47 AM ESTBTIG analyst Mark Massaro lowered the price target on Exact Sciences (NASDAQ: EXAS) to $65.00 (from $75.00) while maintaining a Buy rating.
The analyst comments "Consistent with the company's pre-announce last month, EXAS delivered a modest Q4 revenue beat, as screening and precision oncology in 2024 grew +13% and +4% Y/Y, respectively. In... More
